Your shopping cart is currently empty

Chol-CTPP, a ligand with a dual targeting effect on the blood-brain barrier (BBB) and glioma cells, serves as the precursor to Lip-CTPP when combined with another mitochondria-targeting ligand (Chol-TPP). Lip-CTPP emerges as a potential carrier facilitating the collaborative anti-glioma efficacy of doxorubicin (DOX) and lonidamine (LND). It significantly enhances the inhibition of tumor cell proliferation, migration, and invasion, promotes apoptosis and necrosis, and disrupts mitochondrial function [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Chol-CTPP, a ligand with a dual targeting effect on the blood-brain barrier (BBB) and glioma cells, serves as the precursor to Lip-CTPP when combined with another mitochondria-targeting ligand (Chol-TPP). Lip-CTPP emerges as a potential carrier facilitating the collaborative anti-glioma efficacy of doxorubicin (DOX) and lonidamine (LND). It significantly enhances the inhibition of tumor cell proliferation, migration, and invasion, promotes apoptosis and necrosis, and disrupts mitochondrial function [1]. |
| Molecular Weight | 2884.62 |
| Formula | C144H263N3O53 |
| Smiles | #N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.